MicroRNAs in glaucoma and neurodegenerative diseases

Journal of Human Genetics

Volumn 62, Issue 1, 2017, Pages 105-112

  Molasy, Milena ^a   Walczak, Anna ^a   Szaflik, Jerzy ^b   Szaflik, Jacek P ^b   Majsterek, Ireneusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MESSENGER RNA;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; GLAUCOMA; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; POSTTRANSCRIPTIONAL GENE SILENCING; REVIEW; RNA PROCESSING; RNAI THERAPEUTICS; BIOLOGICAL MODEL; CELL NUCLEUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN SYNTHESIS; RNA TRANSPORT;

CELL NUCLEUS; GENE EXPRESSION REGULATION; GLAUCOMA; HUMANS; MICRORNAS; MODELS, GENETIC; NEURODEGENERATIVE DISEASES; PROTEIN BIOSYNTHESIS; RNA TRANSPORT; RNA, MESSENGER;

EID: 85008600511     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2016.91     Document Type: Review

References (98)

1. Schanen, B. C. & Li, X. Transcriptional regulation of mammalian miRNA genes. Genomics 97, 1-6 (2011).
2. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
3. Li, L., Xu, J., Yang, D., Tan, X. & Wang, H. Computational approaches for microRNA studies: a review. Mamm. Genome 21, 1-12 (2010).
4. Almeida, M. I., Reis, R. M. & Calin, G. A. MicroRNA history: discovery, recent applications, and next frontiers. Mutat. Res. 717, 1-8 (2011).
5. Liu, Z., Sall, A. & Yang, D. MicroRNA: an emerging therapeutic target and intervention tool. Int. J. Mol. Sci. 9, 978-999 (2008).
6. Xu, P., Vernooy, S. Y., Guo, M. & Hay, B. A. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr. Biol. 13, 790-795 (2003).
7. Cho, W. C. S. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 6, 60 (2007).
8. Brennecke, J., Hipfner, D. R., Stark, A., Russell, R. B. & Cohen, S. M. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113, 25-36 (2003).
9. Chen, C.-Z., Li, L., Lodish, H. F. & Bartel, D. P. MicroRNAs modulate hematopoietic lineage differentiation. Science 303, 83-86 (2004).
10. Cai, Y., Yu, X., Hu, S. & Yu, J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 7, 147-154 (2009).
11. Etheridge, A., Lee, I., Hood, L., Galas, D. & Wang, K. Extracellular microRNA: a new source of biomarkers. Mutat. Res. 717, 85-90 (2011).
12. Lewis, B. P., Shih, I., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian MicroRNA targets. Cell 115, 787-798 (2003).
13. Winter, J., Jung, S., Keller, S., Gregory, R. I. & Diederichs, S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228-234 (2009).
14. Araldi, E. & Schipani, E. MicroRNA-140 and the silencing of osteoarthritis. Genes Dev. 24, 1075-1080 (2010).
15. MacRae, I. J., Zhou, K., Li, F., Repic, A., Brooks, A. N., Cande, W. Z. et al. Structural basis for double-stranded RNA processing by Dicer. Science 311, 195-198 (2006).
16. Wu, L. & Belasco, J. G. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol. Cell 29, 1-7 (2008).
17. Nelson, P. T., Wang, W.-X. & Rajeev, B. W. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 18, 130-138 (2008).
18. Gupta, N. & Yücel, Y. H. Glaucoma as a neurodegenerative disease. Curr. Opin. Ophthalmol. 18, 110-114 (2007).
19. Maciotta, S., Meregalli, M. & Torrente, Y. The involvement of microRNAs in neurodegenerative diseases. Front. Cell. Neurosci. 7, 265 (2013).
20. Majsterek, I., Slupianek, A., Hoser, G., Skórski, T. & Blasiak, J. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance? Biochimie 86, 53-65 (2004).
21. Gascon, E. & Gao, F.-B. Cause or effect: misregulation of microRNA pathways in neurodegeneration. Front. Neurosci. 6, 48 (2012).
22. Barbato, C., Ruberti, F. & Cogoni, C. Searching for MIND: microRNAs in neurodegen-erative diseases. BioMed Res. Int. 2009, 871313 (2009).
23. Selkoe, D., Mandelkow, E. & Holtzman, D. Deciphering Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a011460 (2012).
24. O'Brien, R. J. & Wong, P. C. Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 34, 185 (2011).
25. Hernández, F. & Avila, J. The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. FEBS Lett. 582, 3848-3854 (2008).
26. Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N. et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1 β-secretase expression. Proc. Natl Acad. Sci. 105,6415-6420 (2008).
27. Wang, W.-X., Huang, Q., Hu, Y., Stromberg, A. J. & Nelson, P. T. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol. 121, 193-205 (2011).
28. Zong, Y., Wang, H., Dong, W., Quan, X., Zhu, H., Xu, Y. et al. miR-29c regulates BACE1 protein expression. Brain Res. 1395, 108-115 (2011).
29. Zhu, H.-C., Wang, L.-M., Wang, M., Song, B., Tan, S., Teng, J.-F. et al. MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1. Brain Res. Bull. 88, 596-601 (2012).
30. Fang, M., Wang, J., Zhang, X., Geng, Y., Hu, Z., Rudd, J. A. et al. The miR-124 regulates the expression of BACE1 β-secretase correlated with cell death in Alzheimer's disease. Toxicol. Lett. 209, 94-105 (2012).
31. Nelson, P. T. & Wang, W.-X. MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. J Alzheimer's Dis. 21, 75-79 (2010).
32. Yao, J., Hennessey, T., Flynt, A., Lai, E., Beal, M. F. & Lin, M. T. MicroRNA-related cofilin abnormality in Alzheimer's disease. PLoS ONE 5, e15546 (2010).
33. Hébert, S. S., Sergeant, N. & Buée, L. MicroRNAs and the regulation of tau metabolism. Int. J. Alzheimer's Dis. 2012, 406561 (2012).
34. Dickson, J. R., Kruse, C., Montagna, D. R., Finsen, B. & Wolfe, M. S. Alternative polyadenylation and miR-34 family members regulate tau expression. J. Neurochem. 127, 739-749 (2013).
35. Shtilbans, A. & Henchcliffe, C. Biomarkers in Parkinson's disease: an update. Curr. Opin. Neurol. 25, 460-465 (2012).
36. Houlden, H. & Singleton, A. B. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 124, 325-338 (2012).
37. Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E. et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220-1224 (2007).
38. Saiki, S., Sato, S. & Hattori, N. Molecular pathogenesis of Parkinson's disease: update. J. Neurol. Neurosurg. Psychiatry 83, 430-437 (2011).
39. Wang, G., van der Walt, J. M., Mayhew, G., Li, Y.-J., Züchner, S., Scott, W. K. et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α-synuclein. Am. J. Hum. Gen. 82, 283-289 (2008).
40. Mouradian, M. M. MicroRNAs in Parkinson's disease. Neurobiol. Dis. 46, 279-284 (2012).
41. Doxakis, E. Post-transcriptional regulation of α-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 285, 12726-12734 (2010).
42. Junn, E., Lee, K.-W., Jeong, B. S., Chan, T. W., Im, J.-Y. & Mouradian, M. M. Repression of α-synuclein expression and toxicity by microRNA-7. Proc. Natl Acad. Sci. 106,13052-13057 (2009).
43. Khodr, C. E., Pedapati, J., Han, Y. & Bohn, M. C. Inclusion of a portion of the native SNCA 3′ UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia Nigra. Dev. Neurobiol. 72, 906-917 (2012).
44. Gehrke, S., Imai, Y., Sokol, N. & Lu, B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637-641 (2010).
45. Cho, H. J., Liu, G., Jin, S. M., Parisiadou, L., Xie, C., Yu, J. et al. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum. Mol. Genet. 22, 608-620 (2013).
46. Conaco, C., Otto, S., Han, J.-J. & Mandel, G. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc. Natl Acad. Sci. USA 103, 2422-2427 (2006).
47. Siwach, P. & Ganesh, S. Tandem repeats in human disorders: mechanisms and evolution. Front. Biosci. 13, 4467-4484 (2007).
48. Cattaneo, E., Zuccato, C. & Tartari, M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930 (2005).
49. Gil, J. M. & Rego, A. C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27, 2803-2820 (2008).
50. Shoulson, I. & Young, A. B. Milestones in huntington disease. Mov. Disord. 26, 1127-1133 (2011).
51. Savas, J. N., Makusky, A., Ottosen, S., Baillat, D., Then, F., Krainc, D. et al. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc. Natl Acad. Sci. 105, 10820-10825 (2008).
52. Johnson, R., Zuccato, C., Belyaev, N. D., Guest, D. J., Cattaneo, E. & Buckley, N. J. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol. Dis. 29, 438-445 (2008).
53. Lee, S.-T., Chu, K., Im, W.-S., Yoon, H.-J., Im, J.-Y., Park, J.-E. et al. Altered microRNA regulation in Huntington's disease models. Exp. Neurol. 227, 172-179 (2011).
54. Martí, E., Pantano, L., Bañez-Coronel, M., Llorens, F., Miñones-Moyano, E., Porta, S. et al. A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids Res. 38, 7219-7235 (2010).
55. Packer, A. N., Xing, Y., Harper, S. Q., Jones, L. & Davidson, B. L. The bifunctional microRNA miR-9/miR-9∗ regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28, 14341-14346 (2008).
56. Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L. et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76-83 (2003).
57. Bañez-Coronel, M., Porta, S., Kagerbauer, B., Mateu-Huertas, E., Pantano, L., Ferrer, I. et al. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet 8, e1002481 (2012).
58. Sinha, M., Mukhopadhyay, S. & Bhattacharyya, N. P. Mechanism (s) of alteration of micro RNA expressions in Huntington's disease and their possible contributions to the observed cellular and molecular dysfunctions in the disease. Neuromol. Med. 14, 221-243 (2012).
59. Allingham, R. R., Liu, Y. & Rhee, D. J. The genetics of primary open-angle glaucoma: a review. Exp. Eye Res. 88, 837-844 (2009).
60. Weinreb, R. N., Aung, T. & Medeiros, F. A. The pathophysiology and treatment of glaucoma: a review. JAMA 311, 1901-1911 (2014).
61. Dang, H. & Dang, M. M.-H. The impact of obesity and lifestyle-related risk indicators in open-angle glaucoma: a review. Univ. Toronto Med. J. 91, 36-39 (2014).
62. Izzotti, A., Longobardi, M., Cartiglia, C., Rathschuler, F. & Saccà, S. C. Trabecular meshwork gene expression after selective laser trabeculoplasty. PLoS ONE 6, e20110 (2011).
63. Villarreal, G., Oh, D.-J., Kang, M. H. & Rhee, D. J. Coordinated regulation of extracellular matrix synthesis by the microRNA-29 family in the trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 52, 3391-3397 (2011).
64. Vidal-Sanz, M., Salinas-Navarro, M., Nadal-Nicolás, F. M., Alarcón-Martínez, L., Valiente-Soriano, F. J., de Imperial, J. M. et al. Understanding glaucomatous damage: anatomical and functional data from ocular hypertensive rodent retinas. Prog. Retin. Eye Res. 31, 1-27 (2012).
65. Izzotti, A., Ceccaroli, C., Longobardi, M. G., Micale, R. T., Pulliero, A., La Maestra, S. et al. Molecular damage in glaucoma: from anterior to posterior eye segment. The MicroRNA role. MicroRNA 4, 3-17 (2015).
66. Colombo, M., Brittingham, R. J., Klement, J. F., Majsterek, I., Birk, D. E., Uitto, J. et al. Procollagen VII self-assembly depends on site-specific interactions and is promoted by cleavage of the NC2 domain with procollagen C-proteinase. Biochemistry 42, 11434-11442 (2003).
67. Luna, C., Li, G., Qiu, J., Epstein, D. L. & Gonzalez, P. Role of miR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress. Mol. Vis. 15, 2488 (2009).
68. Luna, C., Li, G., Qiu, J., Epstein, D. L. & Gonzalez, P. Cross-talk between miR-29 and transforming growth factor-betas in trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 52, 3567 (2011).
69. Luna, C., Li, G., Huang, J., Qiu, J., Wu, J., Yuan, F. et al. Regulation of trabecular meshwork cell contraction and intraocular pressure by miR-200c. PLoS ONE 7, e51688 (2012).
70. Paylakhi, S. H., Moazzeni, H., Yazdani, S., Rassouli, P., Arefian, E., Jaberi, E. et al. FOXC1 in human trabecular meshwork cells is involved in regulatory pathway that includes miR-204, MEIS2, and ITGβ1. Exp. Eye Res. 111, 112-121 (2013).
71. Luna, C., Li, G., Qiu, J., Epstein, D. L. & Gonzalez, P. MicroRNA-24 regulates the processing of latent TGFβ during cyclic mechanical stress in human trabecular meshwork cells through direct targeting of FURIN. J. Cell Physiol. 226, 1407-1414 (2011).
72. Surgucheva, I., Chidambaram, K., Willoughby, D. A. & Surguchov, A. Matrix metallo-proteinase 9 expression: new regulatory elements. J. Ocul. Biol. Dis. Infor. 3, 41-52 (2010).
73. Sundermeier, T. R. & Palczewski, K. The physiological impact of microRNA gene regulation in the retina. Cell. Mol. Life Sci. 69, 2739-2750 (2012).
74. Lumayag, S., Haldin, C. E., Corbett, N. J., Wahlin, K. J., Cowan, C., Turturro, S. et al. Inactivation of the microRNA-183/96/182 cluster results in syndromic retinal degeneration. Proc. Natl Acad. Sci. 110, 507-516 (2013).
75. Andreeva, K. & Cooper, N. G. MicroRNAs in the neural retina. Int. J. Genomics 2014, 165897 (2014).
76. Kong, N., Lu, X. & Li, B. Downregulation of microRNA-100 protects apoptosis and promotes neuronal growth in retinal ganglion cells. BMC. Mol. Biol. 15, 25 (2014).
77. Jayaram, H., Cepurna, W. O., Johnson, E. C. & Morrison, J. C. MicroRNA expression in the glaucomatous retina MicroRNA expression in the glaucomatous retina. Invest. Ophthalmol. Vis. Sci. 56, 7971-7982 (2015).
78. Gao, L., Jiang, B., Lei, D., Zhou, X. & Yuan, H. Expression profiling of microRNAs in optineurin (E50K) mutant transgenic mice. Biomed. Rep. 4, 193-196 (2016).
79. Chi, Z.-L., Akahori, M., Obazawa, M., Minami, M., Noda, T., Nakaya, N. et al. Overexpression of optineurin E50K disrupts Rab8 interaction and leads to a progressive retinal degeneration in mice. Hum. Mol. Genet. 19, 2606-2615 (2010).
80. Tanaka, Y., Tsuda, S., Kunikata, H., Sato, J., Kokubun, T., Yasuda, M. et al. Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system. Sci. Rep. 4, 5089 (2014).
81. Arora, A., Guduric-Fuchs, J., Harwood, L., Dellett, M., Cogliati, T. & Simpson, D. A. Prediction of microRNAs affecting mRNA expression during retinal development. BMC Dev. Biol. 10, 1 (2010).
82. Baudet, M.-L., Zivraj, K. H., Abreu-Goodger, C., Muldal, A., Armisen, J., Blenkiron, C. et al. miR-124 acts through CoREST to control onset of Sema3A sensitivity in navigating retinal growth cones. Nat. Neurosci. 15, 29-38 (2012).
83. Li, G., Luna, C., Qiu, J., Epstein, D. L. & Gonzalez, P. Modulation of inflammatory markers by miR-146a during replicative senescence in trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 51, 2976-2985 (2010).
84. Alzheimer's Association and others. 2014 Alzheimer's disease facts and figures. Alzheimers Dement. 10, 47-92 (2014).
85. Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117 (2006).
86. Quigley, H. A. & Broman, A. T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262-267 (2006).
87. Junn, E. & Mouradian, M. M. MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol. Ther. 133, 142-150 (2012).
88. Roshan, R., Ghosh, T., Scaria, V. & Pillai, B. MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discov. Today 14, 1123-1129 (2009).
89. Ørom, U. A., Kauppinen, S. & Lund, A. H. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372, 137-141 (2006).
90. Bilen, J., Liu, N., Burnett, B. G., Pittman, R. N. & Bonini, N. M. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol. Cell 24, 157-163 (2006).
91. Conde, J. & Artzi, N. Are RNAi and miRNA therapeutics truly dead? Trends Biotechnol. 33, 141-144 (2015).
92. Conde, J., Edelman, E. R. & Artzi, N. Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: the jack-of-all-trades in cancer nanotheranostics? Adv. Drug Deliv. Rev. 81, 169-183 (2015).
93. Hobel, S. & Aigner, A. Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5, 484-501 (2013).
94. Patel, N., Hoang, D., Miller, N., Ansaloni, S., Huang, Q., Rogers, J. T. et al. MicroRNAs can regulate human APP levels. Mol. Neurodegener. 3, 470 (2008).
95. Liu, W., Liu, C., Zhu, J., Shu, P., Yin, B., Gong, Y. et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. Neurobiol. Aging 33, 522-534 (2012).
96. Long, J. M. & Lahiri, D. K. MicroRNA-101 downregulates Alzheimer's amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem. Biophys. Res. Commun. 404, 889-895 (2011).
97. Delay, C., Calon, F., Mathews, P. & Hébert, S. S. Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function. Mol. Neurodegener. 6, 70 (2011).
98. Boissonneault, V., Plante, I., Rivest, S. & Provost, P. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J. Biol. Chem. 284, 1971-1981 (2009).